Pharmaceuticals Data for Competitive Intelligence and Product Teams

The slice averages 8.09 out of 10 on Datadory's quality score versus the 7.81 catalog-wide mean, and 8 of the 11 records score 8 or higher against 62.8 percent catalog-wide. Sector context and the full industry record sit on the pharmaceuticals data hub.

Diff catalogue snapshots to catch new authorisations, withdrawals and veterinary expansions. 2. Watch recalls, shortages and label changes for early competitive and supply-risk signals. 3. Monitor referrals, PSUSAs and DHPCs for early evidence of competitor regulatory pressure. 4. Watch ChEMBL release cadence (release 37, 2026-05-01) for target-activity shifts relevant to platform positioning. 5. Track monthly RxNorm releases for new-brand and new-ingredient additions as market-entry signals. 6. Track interaction and pathway additions as weak signals of combination-therapy interest areas. 7. Track versioned releases (5.1.22, 2026-06-27) for drug-content changes relevant to portfolio monitoring. 10. Detect label and interaction-content revisions as weak signals of manufacturer strategy changes.

EMA Download Medicine Data Tables is the alert layer: referrals, PSUSAs and DHPCs arrive as XLSX and JSON on a daily cycle, and a PSUSA appearing there is early evidence that a competitor's active ingredient is under EU safety review long before it reaches a news summary. EMA Medicines Catalogue holds the perfect 10/10 quality score in this slice and ships XLSX, JSON and HTML snapshots daily, so diffing consecutive downloads catches new authorisations, withdrawals and veterinary expansions as they post.

1. Wire the three daily regulatory feeds first: schedule downloads of the EMA Medicines Catalogue and EMA Download Medicine Data Tables, and poll the openFDA Drug APIs for recalls, shortages and label changes. 2. Diff for events: compare catalogue snapshots for new authorisations and withdrawals, and flag referrals, PSUSAs and DHPCs as competitor regulatory-pressure alerts. 3. Track market entry monthly through RxNorm / RxNav Browser and APIs new-brand and new-ingredient additions, quarterly through ChEMBL release deltas, and per-version through DrugBank content diffs. 4. Attribute combination-therapy moves using KEGG REST API (DDI and Link Operations) DDI additions, then frame the finding in ATC classes with the WHO ATC/DDD Index. 5. Sweep monthly for backdrop shifts: new FDA datasets indexed in Data.gov Pharmaceutical Datasets, plus Drugs.com label revisions as weak strategy signals.

Cadence across the slice is 7 daily sources, one monthly (RxNorm), one quarterly (ChEMBL), one annual (WHO ATC/DDD) and one static versioned release (DrugBank); catalog-wide, 22.6 percent of datasets.8 percent refresh at least weekly, so this pairing sits on the fast side of the distribution. What the slice cannot supply is consumer-side signal - no review corpus or app-install estimate qualifies for pharmaceuticals here. Broader persona coverage lives under all competitive-intel-product-teams resources.